
    
      This is a randomized, double blind, placebo controlled, multicenter, multinational efficacy
      and safety study in subjects with non small cell lung cancer. Subjects will be evenly
      randomized to placebo or GTx-024 prior to initiation of first line chemotherapy. The primary
      efficacy analysis will be based on total Lean Body Mass (LBM) and physical function.
    
  